Optimal Blue Brings AI-Powered Originator Assistant to Market, Helping Originators Present Best Possible Loan Options to Borrowers
PLANO, Texas, May 1, 2025 (SEND2PRESS NEWSWIRE) — Optimal Blue today announced the general availability of Originator Assistant, a powerful addition to the Optimal Blue PPE. Leveraging generative AI, Originator Assistant eliminates human bias in the loan structuring process and helps originators identify all options for a borrower, providing more ways to help consumers realize the American dream of homeownership.
Unveiled at the inaugural Optimal Blue Summit in February and now available to all Optimal Blue PPE clients using the enhanced originator interface, Originator Assistant is an AI-powered recommendation engine that simplifies loan structuring by identifying alternate scenarios with more competitive pricing. The tool automatically detects pricing breakpoints and suggests opportunities for more strategic loan discussions, saving loan officers time and eliminating manual guesswork. The tool evaluates loan options based on various parameters while searching for pricing incentives on the peripheral or opportunities for adjustment to achieve different terms. Combined with Scenario Optimizer, which enables side-by-side comparisons, Originator Assistant gives lenders a distinct advantage in presenting the best options to borrowers.
Further building on its delivery of innovation, Optimal Blue also announced the beta release of enhanced Lock Extensions workflows, a feature reimagined in close collaboration with the company's clients. The feature gives lenders greater control, automation and flexibility over lock extension policy management. The new Lock Extensions experience allows Optimal Blue PPE users to configure policies across multiple investors using global product groups, significantly reducing manual work and complexity. It also introduces a step-by-step configuration workflow, advanced toggles to support compliance considerations, and automation tools for processing and tracking extension requests. Together, Originator Assistant and Lock Extensions help lenders respond faster to market conditions, reduce manual error and apply lock policies with greater consistency and precision.
'Originator Assistant and our enhanced Lock Extensions feature are great examples of how we listen closely to our customers and build solutions that solve real problems,' said Erin Wester, chief product officer at Optimal Blue. 'These latest enhancements demonstrate that innovation is not just a promise at Optimal Blue, it's a practice. Our clients can continue to expect exciting product updates as Optimal Blue heads toward the MBA Secondary and Capital Markets conference later this month.'
Both enhancements are accessible by Optimal Blue PPE clients with no setup required. Originator Assistant runs automatically, and existing lock extension policies will be migrated to the new Lock Extensions experience, allowing clients to begin making updates right away. Additional innovations introduced at the Optimal Blue Summit, including Rules Optimizer, Ask Obi and the Solution Center, are expected to reach general availability later this spring.
About Optimal Blue
Optimal Blue effectively bridges the primary and secondary mortgage markets to deliver the industry's only end-to-end capital markets platform. The company helps lenders of all sizes and scopes maximize profitability and operate efficiently so they can help American borrowers achieve the dream of homeownership. Through innovative technology, a network of interconnectivity, rich data insights, and expertise gathered over more than 20 years, Optimal Blue is an experienced partner that, in any market environment, allows lenders to optimize their advantage from pricing accuracy to margin protection, and every step in between. To learn more, visit https://OptimalBlue.com/.
LOGO link for media: https://www.Send2Press.com/300dpi/14-0625-s2p-optimal-blue-300dpi.jpg
NEWS SOURCE: Optimal Blue
###
MEDIA ONLY CONTACT:
(not for publication online or in print)
Leslie W. Colley
Depth for Optimal Blue
[email protected]
(678) 622-6229
###
Keywords: Mortgage, Optimal Blue, fintech, Originator Assistant, Optimal Blue PPE, finance AI, mortgage AI, PLANO, Texas
This press release was issued on behalf of the news source (Optimal Blue) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: S2P125900 APNF0325A
To view the original version, visit: https://www.send2press.com/wire/optimal-blue-brings-ai-powered-originator-assistant-to-market-helping-originators-present-best-possible-loan-options-to-borrowers/
© 2025 Send2Press® Newswire, a press release distribution service, Calif., USA.
RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT.
Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
CRSP, ABSI, IRDM: Cathie Wood Offloads $16.4M of CRISPR Therapeutics Stock, Buys Absci and Iridium
Ace hedge fund manager Cathie Wood made some interesting trades on July 25, according to ARK Invest's daily trade updates. Wood sold $16.46 million worth of biotechnology company Crispr Therapeutics (CRSP) and $2.15 million of defense contractor Kratos Defense (KTOS) stock. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Meanwhile, ARK funds added $6.2 million in biotechnology firm Absci Corp. (ABSI), purchased 262,141 shares of genomic diagnostics company Veracyte (VCYT), and acquired 69,969 shares of satellite company Iridium Communications (IRDM). Wood Buys the Dip in Absci Stock On July 25, Wood loaded up on 2.25 million shares of Absci, totaling $6.2 million. Absci leverages generative artificial intelligence (AI) and synthetic biology to develop novel biologic drugs, primarily antibodies, for pharmaceutical and biotechnology partners. ABSI stock plunged 17.7% on Friday after the company announced a $50 million secondary offering of its common shares. Wood seems to have capitalized on the 'dip' in Absci shares to gain a notable position. All seven analysts tracking ABSI stock have rated it a Strong Buy on TipRanks. The average Absci price target of $9.17 implies an impressive 217.3% upside potential from current levels. Year-to-date, ABSI stock has gained 10.3%. Why Is Wood Dumping CRSP Stock? Wood appears to have taken a bearish stance on gene-editing company Crispr, although she maintains a rather optimistic outlook on the overall genomics sector. On Friday, The ARK Innovation ETF (ARKK) sold 190,840 shares of Crispr worth $12.6 million, and the ARK Genomic Revolution ETF (ARKG) sold another 58,268 shares of CRSP for $3.8 million. Crispr is a Swiss-American biotech company focused on developing transformative gene-based medicines to treat serious diseases such as sickle cell disease, beta-thalassemia, various cancers, type 1 diabetes, and cardiovascular diseases. It uses advanced gene-editing technology, primarily its CRISPR/Cas9 platform, to develop its medicines. Despite the latest sale, CRSP remains the largest holding in the ARKG fund, with a market value of $137.5 million, and is also the fourth largest holding in the ARKK fund, with a market value of $450.6 million. Notably, CRSP stock has surged over 64% so far this year, backed by its revolutionary business model. Crispr is expected to release its Q2FY25 results in August. Wall Street expects CRSP to report a diluted loss of $1.4 per share, 1.3% better than the prior year's loss of $1.49. Revenues are expected to jump nearly 1100% year-over-year to $6.14 million. On TipRanks, CRSP stock has a Moderate Buy consensus rating based on 14 Buys and seven Hold ratings. Also, the average Crispr Therapeutics price target of $69.38 implies 7.1% upside potential from current levels. Year-to-date, CRSP stock has soared 64.5%.
Yahoo
2 hours ago
- Yahoo
Why Flowers Foods (FLO) is a Top Food Stock for Dividend Investors
Flowers Foods, Inc. (NYSE:FLO) is included among the 10 Best Food Stocks with Dividends. A female baker in a spotless kitchen carefully decorating a cake. Flowers Foods, Inc. (NYSE:FLO) is an American company that manufactures a range of bakery products for both retail and foodservice markets nationwide. Its offerings include items like fresh bread, buns, rolls, snack cakes, and tortillas. The company supplies these products to grocery stores, convenience outlets, and restaurants. Among its most recognized brands are Nature's Own, Whitewheat, Cobblestone Bread, Wonder, Dave's Killer Bread, Canyon Bakehouse, Mrs. Freshley's, and Tastykake. Flowers Foods, Inc. (NYSE:FLO) has a strong cash position. In the most recent quarter, the company generated $135.6 million in operating cash flow, which grew by $30.5 million. The company also remained committed to its shareholder obligation, returning $52.3 million through dividends during the quarter, up $1.2 million from the previous quarter. Flowers Foods, Inc. (NYSE:FLO) currently offers a quarterly dividend of $0.2475 per share, having raised it by 3.1% in May. This was the company's 23rd consecutive year of dividend growth, which makes it one of the best food stocks with dividends. In addition, it has paid regular dividends to shareholders for 91 quarters in a row. The stock has a dividend yield of 6.09%, as of July 27. While we acknowledge the potential of FLO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: READ NEXT: and Disclosure: None.
Yahoo
3 hours ago
- Yahoo
Trump says he is not seeking summit with Xi, but may visit China
(Reuters) -U.S. President Donald Trump said on Tuesday that he was not seeking a summit with Chinese President Xi Jinping, but added that he may visit China at Xi's invitation, which Trump said had been extended. "I may go to China, but it would only be at the invitation of President Xi, which has been extended. Otherwise, no interest!," Trump said on Truth Social. Aides to Trump and Xi have discussed a potential meeting between the leaders during a trip by the U.S. president to Asia later this year, sources previously told Reuters. A trip would be the first face-to-face encounter between the men since Trump's second term in office, at a time when trade and security tensions between the two superpower rivals remain elevated. While plans for a meeting have not been finalized, discussions on both sides of the Pacific have included a possible Trump stopover around the time of the Asia-Pacific Economic Cooperation summit in South Korea or talks on the sidelines of the October 30-November 1 event, the people said. The third round of U.S.-China trade talks taking place in Stockholm this week may lay the groundwork ahead of a leaders' summit in the autumn, analysts say. A new flare-up of tariffs and export controls would likely impact any plans for a meeting with Xi. Solve the daily Crossword
